Watch for Amputation Concerns With Diabetes Med Invokana
July 2017
Concerns about amputation with canagliflozin (Invokana, etc) will have patients asking about the safety of SGLT2 inhibitors.
This is the latest in a growing list of flozin concerns...ketoacidosis, UTIs, yeast infections, etc.
Amputations, mainly of the toe or mid-foot, are seen in about 6 in 1,000 patients taking canagliflozin per year...compared to about 3 in 1,000 patients per year on other diabetes meds.
Upgrade now to access this resource
This content is not available under the subscriptions purchased by your organization, but you can add it on!
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive